Re N Tox™

What Is Re N Tox™? A Botulinum Toxin Type A Product from South Korea

Re N Tox™ is a botulinum toxin type A injectable manufactured by Pharma Research Bio Co., Ltd. in South Korea.[4][5] Its active ingredient is listed as Clostridium botulinum toxin type A, the same general toxin class used across the aesthetic injection market, including BOTOX®, DYSPORT®, and XEOMIN®.

Some marketing materials describe Re N Tox™ alongside incobotulinumtoxinA products such as XEOMIN® and BOCOUTURE® (Merz), suggesting a shared molecular identity. This comparison requires correction. Re N Tox™ contains Clostridium botulinum toxin type A, but it has not been assigned the incobotulinumtoxinA INN designation and is not identical to XEOMIN®/BOCOUTURE®. No published bioequivalence data or regulatory consensus supports treating them as the same molecule.[1][4] Anyone researching Re N Tox™ reviews or comparisons with Botox should look for manufacturer documentation rather than relying on distributor copy alone.

Formulation and Composition: What the Evidence Actually Supports

Protein composition is one of the more debated points around Re N Tox™. Independent clinical literature identifies Coretox®, a separate South Korean Botox product, as the toxin most consistently documented as manufactured without complexing proteins. Re N Tox™ has not been characterized in the same way.[4]

Commercial descriptions of Re N Tox™ frequently contradict one another. Some listings describe the formulation as “protein-free,” while independent industry reviews report that it uses toxin type A human serum albumin as a stabilizing ingredient, an approach used across many BTX-A products, not only those classified as protein-free.[4] Re N Tox™ cannot be classified as a “naked toxin” unless this is confirmed in an official product monograph from Pharma Research Bio Co., Ltd.

Claims about “low diffusion of the product” or reduced immunogenicity risk appear often in distributor marketing, but they are not validated in peer-reviewed, phase-controlled clinical trials specific to Re N Tox™. In practical terms, diffusion in local areas of the skin is determined mainly by injection volume, dilution ratio, and technique rather than by a proprietary trait unique to any one formulation.[2] We see this confusion regularly across BTX-A brand pages, and practitioners are better served by consulting individual product monographs than by relying on compositional claims that lack published backing.

Re N Tox™ Products: 100U and 200U for Practitioners Who Buy Re N Tox™

Re N Tox™ is available in 100U and 200U lyophilized vial presentations, allowing healthcare professionals to select the format that best fits their treatment protocols and expected dosing requirements.[5]

The 100U vial is commonly chosen for routine aesthetic procedures involving areas such as glabellar lines, forehead lines, and crow’s feet, where lower total dosing may be appropriate.

The 200U presentation offers additional flexibility for clinics performing multiple treatment areas during a single session or for therapeutic applications where larger doses may be indicated, subject to local regulatory approvals.

Both presentations require reconstitution with sterile 0.9% saline before administration and should be prepared according to the manufacturer’s instructions. When practitioners order Re N Tox™ online, their choice of vial size depends on treatment objectives, anticipated patient volume, and established clinical workflows.

Full Re N Tox™ Product Range

The current Re N Tox™ lineup consists of two commercially available presentations. Practitioners planning to order Re N Tox™ wholesale should verify the latest product availability with their supplier, as packaging configurations and regional distribution may change over time.

• Re N Tox™ 100U: Lyophilized botulinum toxin type A supplied in a single-use 100-unit vial.
• Re N Tox™ 200U: Lyophilized botulinum toxin type A supplied in a single-use 200-unit vial.

Reconstitution, Dosage, and Administration

Re N Tox™ dilution follows a process similar to other lyophilized BTX-A products. Sterile 0.9% saline is added to the powder, and the vial is rotated gently rather than shaken, to avoid affecting the toxin protein.[5]

For the 100U vial, commonly cited protocols include:

• 5 mL of saline for a concentration of roughly 4U per 0.1 mL
• 5 mL of saline for a concentration of roughly 2U per 0.1 mL

Storage Guidance

• Unopened vials: 2°C to 8°C
• Reconstituted solution: use within 24 hours, refrigerated between injections
• Do not freeze

Dosing decisions should always follow the manufacturer’s prescribing information and the treating clinician’s judgment. Unit equivalence across different BTX-A products should not be assumed without product-specific clinical data, since botulinum toxin type A formulations are not interchangeable.[1]

Treatment Areas and Indications

Re N Tox™ is used across aesthetic and, in some markets, therapeutic contexts. As with any injection based on botulinum toxin type A, the underlying mechanism is temporary muscle relaxation rather than the volumizing effect of a dermal filler.

Aesthetic applications commonly referenced include:

• Glabellar lines, the vertical lines that form in the forehead between the eyebrows[3]
• Horizontal forehead lines
• Crow’s feet (lateral canthal lines)
• Brow lift
• Masseter reduction
• Lip flip

Therapeutic uses sometimes mentioned in broader Korean BTX-A literature, including excessive sweating (hyperhidrosis) and mouth blepharospasm, are jurisdiction-dependent. These should not be assumed to be approved uses of Re N Tox™ specifically without confirming local labeling.

Regulatory Status

Re N Tox™ has received approval from South Korea’s Ministry of Food and Drug Safety (MFDS), which permits the product to be manufactured and exported to international markets in line with local import requirements.[5]

Re N Tox™ does not hold FDA approval for use in the United States and does not carry a CE mark for the European market. Practitioners within the European Economic Area who are considering non-CE-marked neuromodulators must verify local import regulations and jurisdictional legal frameworks before distributing or administering the product. Regulatory status is market-specific, and all practitioners outside South Korea should confirm current approvals in their own jurisdiction. Hugel’s FDA-approved BTX-A product is LETYBO® (letibotulinumtoxinA), a distinct molecule manufactured by a different company.

When evaluating unit dosing, practitioners should note that botulinum toxin type A products are not interchangeable across brands.[1] Published conversion ratios exist for some products (such as XEOMIN® and BOTOX®), but these should not be extrapolated to Re N Tox™ without dedicated clinical evidence.

Re N Tox™ Compared to Other BTX-A Products

Re N Tox™ vs BOTULAX®

Re N Tox™ and BOTULAX® are both South Korean botulinum toxin type A products, but they come from different manufacturers. BOTULAX®, produced by Hugel, is widely distributed internationally, while Hugel’s related product LETYBO® has received FDA approval in the United States. Re N Tox™, manufactured by Pharma Research Bio Co., Ltd., has received MFDS approval for international distribution but holds neither FDA approval nor a CE mark. No published evidence establishes that the two products differ fundamentally in formulation class, so practitioners should base comparisons on regulatory documentation, available clinical data, and product labeling.

Re N Tox™ vs NABOTA®

NABOTA®, developed by Daewoong, is marketed in the United States as Jeuveau® (prabotulinumtoxinA) and received FDA approval for aesthetic use in 2019. Re N Tox™, by contrast, is manufactured by Pharma Research Bio Co., Ltd. and is distributed internationally under MFDS approval rather than FDA authorization. Both are South Korean botulinum toxin type A products intended for administration by qualified healthcare professionals. No direct head-to-head randomized clinical trials have compared the two, and practitioners should evaluate each according to its approved labeling, clinical data, and regulatory status in their market.

Re N Tox™ vs INNOTOX®

The most notable difference between Re N Tox™ and INNOTOX® is product presentation. INNOTOX®, manufactured by Medytox, is supplied as a ready-to-use liquid formulation, eliminating the need for reconstitution before injection. Re N Tox™ is supplied as a lyophilized powder that requires dilution with sterile saline before use. This difference primarily affects clinical workflow and preparation rather than indicating different treatment outcomes. Practitioners comparing the two should consider handling requirements, manufacturer recommendations, and regulatory approvals rather than assuming equivalence based on product format alone.

Re N Tox™ vs LETYBO®

LETYBO®, produced by Hugel, received FDA approval in 2024 for the temporary improvement of moderate to severe glabellar lines in adults. Re N Tox™ is manufactured by Pharma Research Bio Co., Ltd. and currently holds MFDS approval but carries neither FDA approval nor a CE mark. Although both are South Korean botulinum toxin type A products, Re N Tox™ and LETYBO® are distinct formulations from different manufacturers. For US-based practitioners, LETYBO® is the relevant FDA-cleared Korean BTX-A option. Product selection elsewhere should be guided by local regulatory requirements, approved indications, and manufacturer documentation.

Re N Tox™ vs LIZTOX®

LIZTOX® (Huons) and Re N Tox™ share a broadly similar market position as South Korean botulinum toxin type A products distributed to export markets for use by qualified healthcare professionals.[4] LIZTOX® has expanded into multiple European and Asian markets, while Re N Tox™ is distributed under MFDS approval. At present, there are no published randomized head-to-head studies directly comparing their efficacy or safety. Practitioners should rely on each manufacturer’s prescribing information and available clinical evidence when choosing between them.

Safety and Side Effects

Like other botulinum toxins, Re N Tox™ is associated with generally mild and temporary adverse effects that are most commonly related to the injection procedure itself.[2] Most reactions resolve without treatment within several days when administered by a qualified healthcare professional.

Side effects and precautions to be aware of include:

• Injection-site bruising: Usually mild and short-lived.
• Redness or swelling: Temporary localized reactions that typically subside within a few days.
• Headache: A commonly reported class-wide adverse event following treatment.
• Injection-site discomfort: Mild tenderness or soreness may occur immediately after administration.
• Eyelid ptosis: An uncommon complication following upper-face treatment that is primarily associated with injection placement and technique rather than the product itself.

Re N Tox™ should not be administered to patients with known hypersensitivity to botulinum toxin or any component of the formulation, neuromuscular junction disorders, or active infection at the injection site. Use during pregnancy or breastfeeding should be based on a healthcare professional’s clinical judgment and applicable prescribing guidance. Patients who experience persistent, severe, or unexpected symptoms should seek prompt medical evaluation.[2]

Where to Buy Re N Tox™ Online

Re N Tox™ is a prescription-only pharmaceutical product, and access should always go through licensed, verified channels. Practitioners looking to buy Re N Tox™ wholesale for an existing practice should consider several steps before finalizing a supplier:

• Confirm the distributor’s licensing and authorization to handle prescription BTX-A products
• Verify that temperature-controlled shipping and cold-chain compliance are part of the fulfillment process, since lyophilized BTX-A products are shipping-sensitive by nature
• Request LOT documentation and certificates of authenticity for each shipment
• Check import and licensing requirements specific to your jurisdiction before you order Re N Tox™ online

Order Re N Tox™ Wholesale

Wholesale procurement of prescription BTX-A products follows a different verification path than single-vial orders. Practitioners who order Re N Tox™ wholesale should expect suppliers to require proof of medical licensure, and should themselves confirm that the distributor maintains cold-chain documentation across the full shipment chain. Volume pricing, minimum order thresholds, and available vial configurations (100U and 200U) vary by distributor and jurisdiction. Because Re N Tox™ holds MFDS approval but lacks both FDA clearance and a CE mark, import eligibility depends on the practitioner’s regional regulatory framework.

If you want to purchase Re N Tox™ online, contact the Medical Spa Rx team for guidance on documentation, regulatory considerations, and next steps, whether it’s a first inquiry or an ongoing arrangement to order Re N Tox™ wholesale.

Frequently Asked Questions

What is Re N Tox™?

Re N Tox™ is a botulinum toxin type A injectable manufactured by Pharma Research Bio Co., Ltd. in South Korea. It contains Clostridium botulinum toxin type A and is supplied as a lyophilized powder in Re N Tox™ 100 and Re N Tox™ 200 vial presentations. Before administration, the product must be reconstituted with sterile 0.9% saline and should only be used by qualified healthcare professionals in accordance with local regulations.

Is Re N Tox™ the same as XEOMIN® or BOCOUTURE®?

No. Although Re N Tox™, XEOMIN®, and BOCOUTURE® all belong to the botulinum toxin type A class, Re N Tox™ has not been assigned the incobotulinumtoxinA INN and should not be treated as identical to these products. No published bioequivalence data supports interchangeability. Healthcare professionals should evaluate each product based on its approved labeling, formulation, clinical evidence, and regulatory status.

Is Re N Tox™ FDA approved?

No. Re N Tox™ has received approval from South Korea’s Ministry of Food and Drug Safety (MFDS) but is not approved by the U.S. Food and Drug Administration (FDA). It does not carry a CE mark for the European market. Before using or sourcing the product, practitioners should confirm its regulatory status and approved indications within their own jurisdiction.

How do you dilute Re N Tox™?

Re N Tox™ dilution involves adding sterile 0.9% saline to the lyophilized powder before injection. For the 100U vial, commonly used protocols include 2.5 mL of saline to achieve approximately 4U/0.1 mL or 5 mL for approximately 2U/0.1 mL. After adding the diluent, gently rotate the vial until dissolved rather than shaking it. The reconstituted solution should be refrigerated at 2°C to 8°C and used within 24 hours.

What is Re N Tox™ used for?

Re N Tox™ is primarily used in aesthetic medicine to temporarily soften dynamic facial wrinkles, including glabellar lines, forehead lines, and crow’s feet. Depending on the treatment plan, practitioners may also use it for procedures such as brow lift, masseter reduction, and lip flip. In certain markets, the 200U presentation may be considered for therapeutic applications, including excessive sweating (hyperhidrosis) and mouth blepharospasm, where permitted by local regulations.

What are the side effects of Re N Tox™?

Like other botulinum toxin type A products, Re N Tox™ may cause temporary bruising, redness, swelling, tenderness, or headache following injection. Eyelid ptosis is an uncommon but recognized complication after upper-face treatment and is influenced by injection technique. Re N Tox™ should not be administered to patients with botulinum toxin hypersensitivity, active infection at the injection site, or certain neuromuscular disorders unless clinically appropriate.

Where can practitioners find information on Re N Tox™?

Healthcare professionals researching Re N Tox™ can contact the Medical Spa Rx team for guidance. Representatives can help practitioners locate relevant product information and address questions about documentation or regulatory considerations.

This page and all of its displayed content are intended for medical professionals, for informational purposes only, and are not a substitute for medical advice.

References

[1] Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics. 2014;8:227-241. Published 2014 Oct 6. doi:10.2147/BTT.S65603 

[2] Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004;20(7):981-990. doi:10.1185/030079904125003962 

[3] Lemdani MS, Honig SE, Habarth-Morales TE, et al. Comparison of Botulinum Toxin A Formulations for Glabellar Strain Treatment in Women: A Double-Blind Randomized Clinical Trial. JAMA Dermatol. 2025;161(7):723-730. doi:10.1001/jamadermatol.2025.1335 

[4] Dressler D, Kim N, Johnson EA, Adib Saberi F. Korean botulinum toxins. J Neural Transm (Vienna). 2026;133(6):971-975. doi:10.1007/s00702-025-03076-x

[5] Re N Tox™ (for Export) 100 Units, 200 Units. PharmaResearchBio. http://www.pr-bio.co.kr/eng/bbs/content.php?co_id=business01

Written and reviewed by the Medical Spa Rx Editorial Team 

All clinical and product claims on this page have been checked against peer-reviewed research, manufacturer data, and regulatory sources in accordance with our Editorial Policy .